User login
In an interview at the Joint Conference on the Molecular Origins of Lung Cancer, Dr. Roy Herbst, chief of medical oncology at the Yale Cancer Center in New Haven, Conn., offers his perspectives on new developments in lung cancer screening and treatment, and he discusses the promise that genetically targeted approaches and immunotherapy may offer.
In an interview at the Joint Conference on the Molecular Origins of Lung Cancer, Dr. Roy Herbst, chief of medical oncology at the Yale Cancer Center in New Haven, Conn., offers his perspectives on new developments in lung cancer screening and treatment, and he discusses the promise that genetically targeted approaches and immunotherapy may offer.
In an interview at the Joint Conference on the Molecular Origins of Lung Cancer, Dr. Roy Herbst, chief of medical oncology at the Yale Cancer Center in New Haven, Conn., offers his perspectives on new developments in lung cancer screening and treatment, and he discusses the promise that genetically targeted approaches and immunotherapy may offer.
